Lower CH50 as a predictor for intractable or recurrent lupus enteritis: A retrospective observational study.


Journal

Modern rheumatology
ISSN: 1439-7609
Titre abrégé: Mod Rheumatol
Pays: England
ID NLM: 100959226

Informations de publication

Date de publication:
May 2021
Historique:
pubmed: 21 8 2020
medline: 11 6 2021
entrez: 21 8 2020
Statut: ppublish

Résumé

Lupus enteritis (LE) is a rare but well-known gastrointestinal manifestation of systemic lupus erythematosus (SLE). This study was conducted to identify prognostic factors associated with poor responses in patients with LE. We consecutively registered patients diagnosed with LE between January 2009 and October 2019, and retrospectively compared their clinical characteristics based on whether they had good or poor responses to treatment. A total of 13 patients (17 episodes) were included. The median age was 41 years, and 12 patients were female. A comparison of clinical characteristics between groups revealed similar computed tomography (CT) findings. However, serum CH50 levels were significantly lower in the poor response group (median [interquartile ranges (IQR)]; 29.2 [25.3-46.9] U/mL vs 19.3 [7.8-24.0] U/mL, Lower levels of CH50 at the time of initial treatment predicted inadequate treatment response in patients with LE.

Identifiants

pubmed: 32815450
doi: 10.1080/14397595.2020.1812871
doi:

Substances chimiques

Autoantibodies 0
Glucocorticoids 0
beta 2-Glycoprotein I 0

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

643-648

Auteurs

Yusuke Yoshida (Y)

Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital, Hiroshima, Japan.

Takuji Omoto (T)

Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital, Hiroshima, Japan.
Department of Rheumatology, Hiroshima Prefectural Hospital, Hiroshima, Japan.

Hiroki Kohno (H)

Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital, Hiroshima, Japan.

Tadahiro Tokunaga (T)

Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital, Hiroshima, Japan.

Tatsuomi Kuranobu (T)

Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital, Hiroshima, Japan.

Kazutoshi Yukawa (K)

Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital, Hiroshima, Japan.

Hirofumi Watanabe (H)

Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital, Hiroshima, Japan.

Katsuhiro Oi (K)

Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital, Hiroshima, Japan.

Tomohiro Sugimoto (T)

Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital, Hiroshima, Japan.

Sho Mokuda (S)

Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital, Hiroshima, Japan.

Takaki Nojima (T)

Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital, Hiroshima, Japan.

Shintaro Hirata (S)

Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital, Hiroshima, Japan.

Eiji Sugiyama (E)

Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital, Hiroshima, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH